An observational study in Parkinson Disease and Parkinson's Disease, sponsored by Innopeutics Corporation. Recruiting at 1 site in South Korea. Open to participants aged 50 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-07-01.
Sponsored by Innopeutics Corporation · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 76 studies in Parkinson Disease with a site in Korea, Republic of — 13 open to participants now, 15 under way, 1 of them phase 3. Parkinson Disease · Korea, Republic of.
Among the 76 studies in Parkinson Disease with a site in Korea, Republic of, this one is one of 6 that started in 2026, is one of 9 observational ones, reaches primary completion later than 13 of the 14 other live ones, and was the 75th registered.
4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.
Browse Parkinson Disease studies →13 of the 76 studies in Parkinson Disease with a site in Korea, Republic of are open now. Recruiting first, the newest first:
Innopeutics Corporation · Sites in Korea, Republic of
Ages 50–80
Hoffmann-La Roche · Sites in Korea, Republic of, United States, Australia and 14 more countries
Ages 50–85
Pusan National University Yangsan Hospital · Sites in Korea, Republic of
Ages 40+
Samsung Medical Center · Sites in Korea, Republic of
Ages 50+
Kliniken Beelitz GmbH · Sites in Korea, Republic of, Austria, Germany and 5 more countries
Ages 18+
A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →
Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.
This study: 50 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
76 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 9 · Phase 3 9 · Phase 4 16
First in 2006; this study’s year is marked. 6 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 6 is below the median of 96 across 1,088 observational studies indexed under Parkinson Disease.
Median enrollment 60 across the 67 interventional studies, 500 across the 9 observational. Of the 45 that completed or were terminated, 12 (27%) have results posted.
This tab as a report to print or save as PDF → With an account.
28 of 76 have an industry lead sponsor. The 10 most frequent:
Innopeutics Corporation is the lead sponsor of 2 studies on the registry; 2 are open to participants now.
Innopeutics Corporation has 2 studies filed under Parkinson Disease — fewer than ten, so there is no comparison to draw.
3 of the studies in Parkinson Disease with a site in Korea, Republic of that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07569133Ho-Won LeeEfficacy of Repetitive Transcranial Magnetic Stimulation for Improving Depressive Symptoms in Patients With Parkinson's Disease | 2026-11-27 |
| NCT07522138Seoul National University HospitalHome-based Self-exercise in Patients With Parkinson's Disease: A Feasibility Study | 2026-12-01 |
| NCT01799915NYU Langone HealthNatural History Study of Synucleinopathies | 2026-12-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 76 studies in Parkinson Disease with a site in Korea, Republic of, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the long-term safety of IPS101A and to assess the durability of efficacy in subjects who received IPS101A.
Subject with advanced Parkinson's disease who received IPS101A gene therapy in the Phase 1 clinical trial (IPS101A-10)
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The group of subjects who received IPS101A in the IPS101A-10 clinical trial
Safety Evaluation: Incidence of serious adverse events of special interest
Assess severity and frequency serious adverse events of special interest
Time frame: Baseline to 5 years
Safety Evaluation: Incidence of serious adverse events (SAEs) and adverse events (AEs)
Assess severity and frequency of reported adverse events
Time frame: Baseline to 5 years
Safety Evaluation: Number of participants with clinically-relevant changes in physical exams
The results of the physical examination after administration of the clinical trial drug are compared with those before administration to determine whether clinically significant symptoms occur
Time frame: Baseline to 5 years
Safety Evaluation: Number of participants with clinically-relevant changes in laboratory test
The clinical significance of laboratory test results after administration of a clinical trial drug is confirmed by comparing them with those before administration.
Time frame: Baseline to 5 years
Change from Baseline in Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) scores (defined on/off)
Each symptom is rated on a scale of 0 to 4, with higher scores indicating more severe Parkinson's disease.
Time frame: Baseline to 5 years
Plan to share: No
No publications or documents are linked to this record.
Started May 2026 (actual). Primary completion is estimated for Jul 2031, 62 months after the start.
Of 60 industry-sponsored observational studies under Parkinson Disease, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 64. This study's planned 62 months is above that.
Counting every sponsor, half of 441 studies reached it within 47 months; a quarter within 22 and three quarters within 114.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Innopeutics Corporation